A regulatory perspective on pharmacokinetic/pharmacodynamic modelling

被引:20
作者
Machado, SG
Miller, R
Hu, C
机构
[1] US FDA, Off Biostat, CDER, HFD 705, Rockville, MD 20857 USA
[2] US FDA, Off Clin Pharmacol & Biopharmaceut, Rockville, MD 20857 USA
关键词
D O I
10.1191/096228099674515377
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
We present an integrated summary from statistical and pharmacological perspectives of pharmacokinetic/pharmacodynamic (PK/PD) modelling and its use in drug development and regulation for guiding appropriate dosing. An overview of the technical aspects of PK/PD modelling describes how structural models are constructed and refined using pharmacokinetic and pharmacodynamic principles and how random effects models are used to account for individual differences in desired (and undesired) responses due to patient characteristics. Lastly, we describe applications of PK/PD modelling for the purposes of drug labelling, for resolving a safety concern, and for improving therapeutic monitoring of anaesthetic depth during surgery.
引用
收藏
页码:217 / 245
页数:29
相关论文
共 34 条
[1]  
[Anonymous], 1995, Journal of computational and Graphical Statistics, DOI DOI 10.2307/1390625
[2]  
BEAL SL, 1992, NONMEM USERS GUIDES
[3]  
BISCHOFF KB, 1980, FED PROC, V39, P2456
[4]   PROGRAM PACKAGE FOR SIMULATION AND PARAMETER-ESTIMATION IN PHARMACOKINETIC SYSTEMS [J].
DARGENIO, DZ ;
SCHUMITZKY, A .
COMPUTER PROGRAMS IN BIOMEDICINE, 1979, 9 (02) :115-134
[5]  
DAVIDIAN M, 1993, BIOMETRIKA, V80, P475, DOI 10.1093/biomet/80.3.475
[6]  
Davidian M., 1995, NONLINEAR MODELS REP
[8]  
Efron B., 1994, INTRO BOOTSTRAP, V57, DOI DOI 10.1201/9780429246593
[9]  
Fadiran E. O., 1997, Clinical Pharmacology and Therapeutics, V61, P206
[10]  
FLEISHAKER JC, 1995, HDB PHARMACOKINETIC